Biased Ligands. Better Drugs.

Trevena to Report Third Quarter 2017 Financial Results on November 7, 2017
11/1/17

Trevena, Inc. (NASDAQ:TRVN) today announced that it will host a conference call and webcast on Tuesday, November 7, 2017 at 8:00 am EST to review financial results for the quarter ended September 30, 2017 and to discuss recent corporate highlights.

To join the call, please dial-in at (855) 465-0180 (conference ID: 9796968).

To join a live audio webcast of the call, please visit the Investor Presentation section of the Company’s website (conference ID: 9796968). Following the conclusion of the call, the webcast will be available for replay for 30 days.

About Trevena 

Trevena, Inc. is a biopharmaceutical company focused on providing better, safer therapies to patients in pain.  The Company has leveraged breakthrough science to discover and develop its investigational product OLINVO™ (oliceridine injection) for the management of moderate-to-severe acute pain.  OLINVO has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration and was designed to provide healthcare providers an innovative new option for patients who would otherwise require conventional intravenous opioids.  The Company has an early stage pipeline of new chemical entities targeting novel mechanisms of action, including for acute migraine, neuropathic pain, and other indications.

Contacts

Trevena, Inc.

Investors:
Jonathan Violin, Ph.D.
Vice President, Corporate Strategy & Investor Relations
610-354-8840 x231
jviolin@trevena.com

or

Media:
Public Relations
PR@trevena.com

Copyright © Trevena, Inc.